Since 2004, Doyle has served as executive chairman of the global oncology company Novocure GmbH. Novocure is a pioneer in the technique of Tumor Treating Fields, a new therapeutic modality for solid tumors that targets the electrical properties of cells rather than their chemical properties to selectively kill cancer cells and extend patient survival. Novocure conducted the only successful phase-3 trial in 23 years for the treatment of glioblastoma and has treated 30,000+ patients with this form of brain cancer in the commercial setting. Recently, Novocure announced the success of the LUNAR phase-3 trial in metastatic non-small cell lung cancer.
Previously, as an executive of Johnson & Johnson, Doyle was chairman of the company’s Medical Devices Research and Development Council, worldwide president of Biosense-Webster and a member of the internal boards of directors of Cordis Corporation and Johnson & Johnson Development Corporation, J&J’s private equity subsidiary.
Doyle received a Bachelor of Science degree in materials science and engineering from MIT and an M.B.A. from Harvard Business School. Bill serves on MIT’s Institute of Medical Engineering & Science (IMES) Visiting Committee, Harvard Business School’s Healthcare Advisory Board, and is an emeritus member of Harvard Business School’s Board of Dean’s Advisors on which he served for 10 years. Doyle serves as an adviser to the Harvard joint MS/MBA program and previously served on the MIT Undergraduate and Graduate Education Visiting Committee. He also serves on the Governing Board of the Pershing Square Sohn Cancer Research Alliance.
Doyle lives in Portsmouth, New Hampshire, with his wife Stephanie and salukis Rumi and Rilke. Daughter Marilyn is a member of the Form of 2025 and son Finnegan is a 7th grader at Berwick Academy in Maine.